Home › Decisions › BMRN 2026-02-27

BMRN FDA decision — Feb 27, 2026

✓ APPROVED

BioMarin Pharmaceutical Inc. — PALYNZIQ (pegvaliase-pqpz) - (PEGASUS) · Phenylketonuria (PKU) in adolescents aged 12-17.

Run-up into the decision (T-120 → T+5)

Daily close, T-120 (9/12/25) through T+5. Run-up high $64.08 on 2/20/26, low $51.46 on 11/14/25 (T-120 to T-1). FDA decision 2/27/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-02-27

OutcomeApproved

Drug / candidatePALYNZIQ (pegvaliase-pqpz) - (PEGASUS)

CompanyBioMarin Pharmaceutical Inc.

120-day run-up (T-120→T-1)+5.8%